Bronchogen
Bronchial bioregulator peptide
Respiratory tissue bioregulator.
Half-life
~ hours
Mol. weight
446.5 g/mol (C18H30N4O9)
Sequence
Ala-Glu-Asp-Leu (AEDL)
Discussions
0 threads
Overview
A short bioregulator peptide in the Khavinson tradition of very small (often 2–5 amino-acid) peptides proposed to regulate gene expression in a tissue-specific way — here, targeting bronchial epithelium. Unlike classical signaling peptides that act through defined receptors, bioregulators are hypothesized to modulate transcription directly, an elegant concept with an evidence base concentrated in a single Russian research lineage.
Mechanism of action
Bronchogen belongs to the bioregulator class developed by V. Khavinson and colleagues, who proposed that very short peptides (di- to pentapeptides) can translocate to the nucleus and modulate tissue-specific gene expression. Bronchogen is studied for regulating gene expression in bronchial epithelium, with proposed support for respiratory mucosa function and tissue repair. The mechanism is fundamentally different from receptor-binding peptides: it is transcriptional regulation by extremely short sequences, which is intriguing but mechanistically less characterized than mainstream peptide pharmacology.
Researched benefits
- Studied for bronchial tissue support
- Short, tissue-targeted bioregulator format
- Proposed to support respiratory mucosa function
Considerations
- Evidence concentrated in one Russian research tradition
- Human data limited and not independently replicated at scale
- Mechanism of gene regulation by ultra-short peptides not fully established
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Bronchogen in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Bronchogen:
View Bronchogen index on PubMed (NCBI)